ESTERO, FL / ACCESS Newswire / August 14, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), developer of a multi-faceted patent-pending drug and supplement delivery technology, today announced that Kraig Higginson, Interim Chief Executive Officer of Aspire, will be presenting at the upcoming Sidoti Virtual Investor Conference on August 20 at 1:45 PM Eastern. Investors and other interested individuals may access the virtual presentation here: https://sidoti.zoom.us/webinar/register/WN_5UneWjXKTOuzgbB4wpeByg
One-on-One Meetings
Aspire will also host virtual one-on-ones with investors on Wednesday, August 20 and Thursday, August 21, 2025. To register for the presentation or one-on ones, visit https://sidoti.com/events.
A replay of the presentation will be available on the investor relations section of Aspire’s website at https://ir.aspirebiolabs.com/events/
About Aspire Biopharma, Inc.
Aspire Biopharma has developed a patent-pending disruptive technology that can deliver supplements and drugs to the body rapidly and precisely with less negative impact to the system by going directly to the bloodstream and avoiding the gastrointestinal tract. For more information, please visit www.aspirebiolabs.com.
Aspire Biopharma Holdings, Inc.
Contact
PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com
SOURCE: Aspire Biopharma Holdings, Inc.
View the original press release on ACCESS Newswire
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…